OncoMatch/Clinical Trials/NCT04150744
RFA Plus Carrizumab vs Carrizumab Alone for HCC
Is NCT04150744 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies radiofrequency ablation for tumor immunity.
Treatment: radiofrequency ablation — The study aims to find whether patients with advanced HCC can get more benefits from RFA +PD-1 immunosuppressant (carrizumab) compared with carrizumab alone, considering with the result of PFS.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Disease stage
Required: Stage BCLC B, BCLC C
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: local ablation
Have local ablation...in 3 months before enrolled.
Cannot have received: TACE
Have...TACE...in 3 months before enrolled.
Cannot have received: radiotherapy
Have...radiotherapy in 3 months before enrolled.
Cannot have received: anti-tumor vaccine and other immunostimulate anti-tumor drugs
Patients have anti-tumor vaccine and other immunostimulate anti-tumor drugs in 3 months
Lab requirements
Kidney function
Routine urine test showed urinary protein ≥++ or the 24 hours amount of urinary protein ≥1.0 g [excluded]
Liver function
Child-Pugh Score: A or B
Cardiac function
Have type II myocardial ischemia or myocardial infarction, uncontrollable arrhythmia [excluded]
The function of main organs normal; Child-Pugh Score: A or B; Routine urine test showed urinary protein ≥++ or the 24 hours amount of urinary protein ≥1.0 g [excluded]; Have type II myocardial ischemia or myocardial infarction, uncontrollable arrhythmia [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04150744 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage BCLC B or BCLC C is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify